LPC
OACCW

Lineage Point Capital’s Oaktree Acquisition Corp III Life Sciences Warrant OACCW Stock Holding History

Lineage Point Capital’s Portfolio OACCW Stock Details OACCW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$74.3K Buy
+78,928
New +$66.3K 0.02% 256

Other funds holding OACCW

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BGGS
Boussard & Gavaudan Gestion SAS Paris, France $1.99B AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Lineage Point Capital's OACCW Position: Q2 2026 in Review

Lineage Point Capital opened a new position in Oaktree Acquisition Corp III Life Sciences Warrant (OACCW) in Q2 2026: 78,928 shares worth $74.3K. The stake represents 0.02% of the portfolio and ranks #256 among its holdings.

27 funds tracked by Wall St. Rank hold OACCW as of Q2 2026.

  • Lineage Point Capital held 78,928 shares of Oaktree Acquisition Corp III Life Sciences Warrant worth $74.3K as of Q2 2026.
  • Oaktree Acquisition Corp III Life Sciences Warrant was a new Lineage Point Capital position in Q2 2026.
  • Oaktree Acquisition Corp III Life Sciences Warrant made up 0.02% of Lineage Point Capital's portfolio in Q2 2026, its #256 holding.
  • 27 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences Warrant as of Q2 2026.

Based on Lineage Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.